Basket cover image
17 handpicked stocks

The North Ablaze: Investing In Wildfire Resilience

This carefully selected group of stocks offers exposure to companies tackling Canada's unprecedented wildfire crisis. Our professional analysts have identified businesses positioned to benefit from increased spending on wildfire suppression, air quality solutions, and carbon monitoring technologies.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+7

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 21

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

BAER

Bridger Aerospace Group Holdings Inc

BAER

Current price

$1.55

PRM

PERIMETER SOLUTIONS SA

PRM

Current price

$18.53

MSA

MSA Safety Inc

MSA

Current price

$171.28

It only takes 60 seconds.

About This Group of Stocks

1

Our Expert Thinking

Canada's severe wildfire season is creating urgent, non-discretionary demand for climate adaptation solutions. This crisis is driving government and private investment into specialized companies across firefighting, environmental monitoring, air quality, and carbon management sectors.

2

What You Need to Know

This investment theme focuses on companies providing critical solutions to escalating wildfire challenges. These businesses operate across the entire response chain, from firefighting and protective equipment to air filtration and carbon measurement technologies.

3

Why These Stocks

These companies were selected for their specialized capabilities in addressing different aspects of wildfire response and recovery. They represent tactical opportunities in a growing market where climate-related disasters are increasing the demand for adaptive technologies.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+164.45%

Group Performance Snapshot

164.45%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 164.45% over the next year.

16 of 17

Stocks Rated Buy by Analysts

16 of 17 assets in this group are rated Buy by professional analysts.

375.1% vs 4%

Group Growth vs Bank interest

This group averaged a 375.1% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🔥

Climate Crisis Creates Opportunity

As wildfire seasons worsen, governments are being forced into urgent, non-discretionary spending on prevention and recovery. These companies are positioned to capture this growing, recession-resistant funding.

💨

Clean Air Is Non-Negotiable

With millions exposed to dangerous smoke conditions, air quality solutions are becoming essential infrastructure rather than luxury goods. Public health demands are driving innovation and adoption across these companies.

📊

Carbon Accountability Is Coming

The massive, underestimated carbon release from these fires highlights the need for better measurement technology. Companies in this space are developing solutions that governments and businesses increasingly can't afford to ignore.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.